Global Multiple Myeloma Therapeutics Market Size, Status and Forecast 2019-2025

Published On: Jul 2019

Format: PDF

Publisher: QY Research

Pages: 95

Report ID: 19382

Multiple Myeloma (MM) is a haematological malignancy considered by the propagation of plasma cells in the bone marrow. The disease is incurable; though over the few years there have been substantial developments in therapy, determined by a greater understanding of pathophysiology. Multiple myeloma is common among men as compared to women and also arises commonly with growing age.
In 2018, the global Multiple Myeloma Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Multiple Myeloma Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Multiple Myeloma Therapeutics development in United States, Europe and China.

The key players covered in this study
Janssen Biotech, Inc.
Bristol-Myers Squibb
Novartis AG
Bristol-Myers Squibb Company
Millennium Pharmaceuticals
Celgene Corporation
Kesios Therapeutics Limited
Amgene, Inc.
Genzyme Corporation
Juno Therapeutics

Market segment by Type, the product can be split into
Chemotherapy And Other Drugs
Radiation
Stem Cell Transplant
Other Supportive Treatments

Market segment by Application, split into
Hospitals
Clinics
Others

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Multiple Myeloma Therapeutics status, future forecast, growth opportunity, key market and key players.
To present the Multiple Myeloma Therapeutics development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Multiple Myeloma Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Multiple Myeloma Therapeutics Market Size Growth Rate by Type (2014-2025)
1.4.2 Chemotherapy And Other Drugs
1.4.3 Radiation
1.4.4 Stem Cell Transplant
1.4.5 Other Supportive Treatments
1.5 Market by Application
1.5.1 Global Multiple Myeloma Therapeutics Market Share by Application (2014-2025)
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Multiple Myeloma Therapeutics Market Size
2.2 Multiple Myeloma Therapeutics Growth Trends by Regions
2.2.1 Multiple Myeloma Therapeutics Market Size by Regions (2014-2025)
2.2.2 Multiple Myeloma Therapeutics Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Multiple Myeloma Therapeutics Market Size by Manufacturers
3.1.1 Global Multiple Myeloma Therapeutics Revenue by Manufacturers (2014-2019)
3.1.2 Global Multiple Myeloma Therapeutics Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Multiple Myeloma Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2 Multiple Myeloma Therapeutics Key Players Head office and Area Served
3.3 Key Players Multiple Myeloma Therapeutics Product/Solution/Service
3.4 Date of Enter into Multiple Myeloma Therapeutics Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Multiple Myeloma Therapeutics Market Size by Type (2014-2019)
4.2 Global Multiple Myeloma Therapeutics Market Size by Application (2014-2019)

5 United States
5.1 United States Multiple Myeloma Therapeutics Market Size (2014-2019)
5.2 Multiple Myeloma Therapeutics Key Players in United States
5.3 United States Multiple Myeloma Therapeutics Market Size by Type
5.4 United States Multiple Myeloma Therapeutics Market Size by Application

6 Europe
6.1 Europe Multiple Myeloma Therapeutics Market Size (2014-2019)
6.2 Multiple Myeloma Therapeutics Key Players in Europe
6.3 Europe Multiple Myeloma Therapeutics Market Size by Type
6.4 Europe Multiple Myeloma Therapeutics Market Size by Application

7 China
7.1 China Multiple Myeloma Therapeutics Market Size (2014-2019)
7.2 Multiple Myeloma Therapeutics Key Players in China
7.3 China Multiple Myeloma Therapeutics Market Size by Type
7.4 China Multiple Myeloma Therapeutics Market Size by Application

8 Japan
8.1 Japan Multiple Myeloma Therapeutics Market Size (2014-2019)
8.2 Multiple Myeloma Therapeutics Key Players in Japan
8.3 Japan Multiple Myeloma Therapeutics Market Size by Type
8.4 Japan Multiple Myeloma Therapeutics Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Multiple Myeloma Therapeutics Market Size (2014-2019)
9.2 Multiple Myeloma Therapeutics Key Players in Southeast Asia
9.3 Southeast Asia Multiple Myeloma Therapeutics Market Size by Type
9.4 Southeast Asia Multiple Myeloma Therapeutics Market Size by Application

10 India
10.1 India Multiple Myeloma Therapeutics Market Size (2014-2019)
10.2 Multiple Myeloma Therapeutics Key Players in India
10.3 India Multiple Myeloma Therapeutics Market Size by Type
10.4 India Multiple Myeloma Therapeutics Market Size by Application

11 Central & South America
11.1 Central & South America Multiple Myeloma Therapeutics Market Size (2014-2019)
11.2 Multiple Myeloma Therapeutics Key Players in Central & South America
11.3 Central & South America Multiple Myeloma Therapeutics Market Size by Type
11.4 Central & South America Multiple Myeloma Therapeutics Market Size by Application

12 International Players Profiles
12.1 Janssen Biotech, Inc.
12.1.1 Janssen Biotech, Inc. Company Details
12.1.2 Company Description and Business Overview
12.1.3 Multiple Myeloma Therapeutics Introduction
12.1.4 Janssen Biotech, Inc. Revenue in Multiple Myeloma Therapeutics Business (2014-2019)
12.1.5 Janssen Biotech, Inc. Recent Development
12.2 Bristol-Myers Squibb
12.2.1 Bristol-Myers Squibb Company Details
12.2.2 Company Description and Business Overview
12.2.3 Multiple Myeloma Therapeutics Introduction
12.2.4 Bristol-Myers Squibb Revenue in Multiple Myeloma Therapeutics Business (2014-2019)
12.2.5 Bristol-Myers Squibb Recent Development
12.3 Novartis AG
12.3.1 Novartis AG Company Details
12.3.2 Company Description and Business Overview
12.3.3 Multiple Myeloma Therapeutics Introduction
12.3.4 Novartis AG Revenue in Multiple Myeloma Therapeutics Business (2014-2019)
12.3.5 Novartis AG Recent Development
12.4 Bristol-Myers Squibb Company
12.4.1 Bristol-Myers Squibb Company Company Details
12.4.2 Company Description and Business Overview
12.4.3 Multiple Myeloma Therapeutics Introduction
12.4.4 Bristol-Myers Squibb Company Revenue in Multiple Myeloma Therapeutics Business (2014-2019)
12.4.5 Bristol-Myers Squibb Company Recent Development
12.5 Millennium Pharmaceuticals
12.5.1 Millennium Pharmaceuticals Company Details
12.5.2 Company Description and Business Overview
12.5.3 Multiple Myeloma Therapeutics Introduction
12.5.4 Millennium Pharmaceuticals Revenue in Multiple Myeloma Therapeutics Business (2014-2019)
12.5.5 Millennium Pharmaceuticals Recent Development
12.6 Celgene Corporation
12.6.1 Celgene Corporation Company Details
12.6.2 Company Description and Business Overview
12.6.3 Multiple Myeloma Therapeutics Introduction
12.6.4 Celgene Corporation Revenue in Multiple Myeloma Therapeutics Business (2014-2019)
12.6.5 Celgene Corporation Recent Development
12.7 Kesios Therapeutics Limited
12.7.1 Kesios Therapeutics Limited Company Details
12.7.2 Company Description and Business Overview
12.7.3 Multiple Myeloma Therapeutics Introduction
12.7.4 Kesios Therapeutics Limited Revenue in Multiple Myeloma Therapeutics Business (2014-2019)
12.7.5 Kesios Therapeutics Limited Recent Development
12.8 Amgene, Inc.
12.8.1 Amgene, Inc. Company Details
12.8.2 Company Description and Business Overview
12.8.3 Multiple Myeloma Therapeutics Introduction
12.8.4 Amgene, Inc. Revenue in Multiple Myeloma Therapeutics Business (2014-2019)
12.8.5 Amgene, Inc. Recent Development
12.9 Genzyme Corporation
12.9.1 Genzyme Corporation Company Details
12.9.2 Company Description and Business Overview
12.9.3 Multiple Myeloma Therapeutics Introduction
12.9.4 Genzyme Corporation Revenue in Multiple Myeloma Therapeutics Business (2014-2019)
12.9.5 Genzyme Corporation Recent Development
12.10 Juno Therapeutics
12.10.1 Juno Therapeutics Company Details
12.10.2 Company Description and Business Overview
12.10.3 Multiple Myeloma Therapeutics Introduction
12.10.4 Juno Therapeutics Revenue in Multiple Myeloma Therapeutics Business (2014-2019)
12.10.5 Juno Therapeutics Recent Development

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details